The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma-Reference-Cited by-同舟云学术

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Published:2016-12 Issue:1 Volume:4 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

McNeel Douglas G.,Bander Neil H.,Beer Tomasz M.,Drake Charles G.,Fong Lawrence,Harrelson Stacey,Kantoff Philip W.,Madan Ravi A.,Oh William K.,Peace David J.,Petrylak Daniel P.,Porterfield Hank,Sartor Oliver,Shore Neal D.,Slovin Susan F.,Stein Mark N.,Vieweg Johannes,Gulley James L.

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-016-0198-x.pdf

Reference61 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi: 10.3322/caac.21332 .

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi: 10.3322/caac.21254 .

3. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273(7):548–52.

4. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. doi: 10.1056/NEJMoa1207506 .

5. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–92. doi: 10.1016/s1470-2045(12)70379-0 .

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anticancer actions of carnosine in cellular models of prostate cancer;Journal of Cellular and Molecular Medicine;2023-11-29

2. What should be the future direction of development in the field of prostate cancer with lung metastasis?;World Journal of Clinical Oncology;2023-10-24

3. Adaptive Immunity in Genitourinary Cancers;European Urology Oncology;2023-06

4. Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy;Frontiers in Immunology;2023-01-10

5. A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8+ T Cells with Ex Vivo Cytotoxic Capacities in HHDII/DR1 Transgenic Mice;Cancers;2022-04-13